参考文献/References:
[1] Petrulea MS, Plantinga TS, Smit JW, et al. PI3K/Akt/mTOR: a promising therapeutic target for non-medullary thyroid carcinoma[J].Cancer Treat Rev,2015,41(8):707-713. DOI:10.1016/j.ctrv.2015.06.005.
[2] Viglietto G, Amodio N, Malanga D,et al. Contribution of PKB/AKT signaling to thyroid cancer[J].Front Biosci(Landmark Ed),2011,16:1461-1487.
[3] Onishi K, Zandstra PW. LIF signaling in stem cells and development[J].Development,2015,142(13):2230-2236. DOI:10.1242/dev.117598.
[4] Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6[J].Int J Biol Sci,2012,8(9):1237-1247. DOI:10.7150/ijbs.4989.
[5] Resemann HK, Watson CJ, Lloyd-Lewis B. The Stat3 paradox: a killer and an oncogene[J].Mol Cell Endocrinol,2014,382(1):603-611. DOI:10.1016/j.mce.2013.06.029.
[6] Albi E, Curcio F, Spelat R,et al. The thyroid lobes: the different twins[J].Arch Biochem Biophys,2012,518(1):16-22. DOI:10.1016/j.abb.2011.12.001.
[7] Staab J, Barth PJ, Meyer T. Cell-type-specific expression of STAT transcription factors in tissue samples from patients with lymphocytic thyroiditis[J].Endocr Pathol,2012,23(3):141-150. DOI:10.1007/s12022-012-9204-0.
[8] Ardito G, Revelli L, Boninsegna A,et al. Immunohistochemical evaluation of inflammatory and proliferative markers in adjacent normal thyroid tissue in patients undergoing total thyroidectomy: results of a preliminary study[J].J Exp Clin Cancer Res,2010,29:77. DOI:10.1186/1756-9966-29-77.
[9] Cao W, Liu Y, Zhang R, et al. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells[J].Sci Rep,2015,5:8477. DOI:10.1038/srep08477.
[10] 李智, 郎晓讴, 张绍军, 等. STAT3和STAT5在分化型甲状腺癌组织中的表达及意义[J].吉林大学学报(医学版), 2010, 36(4):708-712.
[11] Kim WG, Choi HJ, Kim WB, et al. Basal STAT3 activities are negatively correlated with tumor size in papillary thyroid carcinomas[J].J Endocrinol Invest,2012,35(4):413-418. DOI:10.3275/7907.
[12] Yan LI, Li LI, Li Q, et al. Expression of signal transducer and activator of transcription 3 and its phosphorylated form is significantly upregulated in patients with papillary thyroid cancer[J]. Exp Ther Med,2015,9(6):2195-2201. DOI:10.3892/etm.2015.2409.
[13] Zhang J, Gill A, Atmore B, et al. Upregulation of the signal transducers and activators of transcription 3(STAT3)pathway in lymphatic metastases of papillary thyroid cancer[J].Int J Clin Exp Pathol,2011,4(4):356-362.
[14] Dong W, Cui J, Tian X,et al. Aberrant sonic hedgehog signaling pathway and STAT3 activation in papillary thyroid cancer[J].Int J Clin Exp Med,2014,7(7):1786-1793.
[15] Jacqueline FB, Melissa H, Wrzesczynska B, et al. STAT3 as an oncogene[J]. Cell, 1999, 98(8): 295-303.
[16] Kim YR, Byun HS, Won M,et al. Modulatory role of phospholipase D in the activation of signal transducer andactivator of transcription(STAT)-3 by thyroid oncogenic kinase RET/PTC[J].BMC Cancer, 2008,8:144. DOI:10.1186/1471-2407-8-144.
[17] Lin H, Chen MC, Chiu CY,et al. Cdk5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells[J].J Biol Chem,2007,282(5):2776-2784. DOI:10.1074/jbc.M607234200.
[18] Kim TH, Lee SY, Rho JH,et al. Mutant p53(G199V)gains antiapoptotic function through signal transducer and activator of transcription 3 in anaplastic thyroid cancer cells[J].Mol Cancer Res,2009,7(10):1645-1654. DOI:10.1158/1541-7786.MCR-09-0117.
[19] Masago K, Asato R, Fujita S,et al. Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma[J].Int J Cancer,2009,124(11):2744-2749. DOI:10.1002/ijc.24250.
[20] Couto JP, Daly L, Almeida A,et al. STAT3 negatively regulates thyroid tumorigenesis[J].Proc Natl Acad Sci U S A,2012,109(35):E2361-E2370. DOI:10.1073/pnas.1201232109.
[21] Couto JP, Almeida A, Daly L,et al. AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines[J].PLoS One,2012,7(10):e46869. DOI:10.1371/journal.pone.0046869.
[22] Wang GM, Ren ZX, Wang PS,et al. Plasmid-based Stat3-specific siRNA and GRIM-19 inhibit the growth of thyroid cancer cells in vitro and in vivo[J].Oncol Rep,2014,32(2):573-580. DOI:10.3892/or.2014.3233.
相似文献/References:
[1]张蓉,俞立波,李连喜.组蛋白修饰与甲状腺癌[J].国际内分泌代谢杂志,2014,(05):348.[doi:10.3760/cma.j.issn.1673-4157.2014.05.017]
Zhang Rong,Yu Libo,Li Lianxi..Histone modification and thyroid tumor[J].International Journal of Endocrinology and Metabolism,2014,(05):348.[doi:10.3760/cma.j.issn.1673-4157.2014.05.017]
[2]李兴佳,徐书杭,刘超.雌激素及其受体与甲状腺癌的关系[J].国际内分泌代谢杂志,2016,36(04):273.[doi:10.3760/cma.j.issn.1673-4157.2016.04.15]
Li Xingjia,Xu Shuhang,Liu Chao.Relationship between estrogen, its receptors and thyroid cancer[J].International Journal of Endocrinology and Metabolism,2016,36(05):273.[doi:10.3760/cma.j.issn.1673-4157.2016.04.15]
[3]郑仁东,刘超.白细胞介素-6与甲状腺疾病[J].国际内分泌代谢杂志,2016,36(05):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
Zheng Rendong,Liu Chao.Interleukin-6 and thyroid disease[J].International Journal of Endocrinology and Metabolism,2016,36(05):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
[4]孟祥慧 徐书杭 陈国芳 刘超.二甲双胍在甲状腺癌防治中的作用[J].国际内分泌代谢杂志,2018,38(04):237.[doi:10.3760/cma.j.issn.1673-4157.2018.04.005]
Meng Xianghui*,Xu Shuhang,Chen Guofang,et al.Role of metformin in prevention and treatment of thyroid cancer[J].International Journal of Endocrinology and Metabolism,2018,38(05):237.[doi:10.3760/cma.j.issn.1673-4157.2018.04.005]
[5]曹星月 武晓泓.基因拷贝数异常在甲状腺癌诊断和预后判断中的
应用进展[J].国际内分泌代谢杂志,2019,39(01):29.[doi:10.3760/cma.j.issn.1673-4157.2019.01.007]
Cao Xingyue,Wu Xiaohong.Progress in the application of gene copy number variations in diagnosis and prognosis of thyroid cancer[J].International Journal of Endocrinology and Metabolism,2019,39(05):29.[doi:10.3760/cma.j.issn.1673-4157.2019.01.007]
[6]张会峰 胡天赤 陈学勤 叶向荣 刘超.丙型肝炎病毒感染与自身免疫性甲状腺疾病
及甲状腺癌风险[J].国际内分泌代谢杂志,2019,39(02):128.[doi:10.3760/cma.j.issn.1673-4157.2019.02.014]
Zhang Huifeng,Hu Tianchi,Chen Xueqin,et al.Relationship between hepatitis C virus infection and the risk of autoimmune thyroid diseases and thyroid cancer[J].International Journal of Endocrinology and Metabolism,2019,39(05):128.[doi:10.3760/cma.j.issn.1673-4157.2019.02.014]
[7]张玉洁 孟召伟 章明放 宋丽丽 李宁.甲状腺疾病的代谢组学研究现状[J].国际内分泌代谢杂志,2019,39(03):173.[doi:10.3760/cma.j.issn.1673-4157.2019.03.007]
Zhang Yujie,Meng Zhaowei,Zhang Mingfang,et al.Research status of metabolomics in thyroid diseases[J].International Journal of Endocrinology and Metabolism,2019,39(05):173.[doi:10.3760/cma.j.issn.1673-4157.2019.03.007]
[8]田勍,洪天配.甲状腺结节诊治过程中的难点与应对[J].国际内分泌代谢杂志,2021,41(06):557.[doi:10.3760/cma.j.cn121383-20210727-07074]
Tian Qing,Hong Tianpei..Difficulties and countermeasures in the diagnosis and treatment of thyroid nodules[J].International Journal of Endocrinology and Metabolism,2021,41(05):557.[doi:10.3760/cma.j.cn121383-20210727-07074]
[9]张雅,相萍萍,徐书杭,等.经皮无水乙醇注射治疗甲状腺结节:老方法的新认识[J].国际内分泌代谢杂志,2022,42(06):469.[doi:10.3760/cma.j.cn121383-20210926-09075]
Zhang Ya,Xiang Pingping,Xu Shuhang,et al.Percutaneous ethanol ablation for thyroid nodules: new perspectives on an old paradigm[J].International Journal of Endocrinology and Metabolism,2022,42(05):469.[doi:10.3760/cma.j.cn121383-20210926-09075]